Scorpius Holdings, Inc. Announces Closing of Public Offering
August 19 2024 - 1:08PM
Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius”, or the
“Company”), an integrated contract development and manufacturing
organization (CDMO), today announced the closing of its
underwritten public offering of 14,375,000 shares of common stock
(and/or pre-funded warrants (“Pre-Funded Warrants”) in lieu
thereof), including full exercise of the underwriter’s
over-allotment option. Each share of common stock (or Pre-Funded
Warrant) was offered at a public offering price of $1.00 per share
(inclusive of the Pre-Funded Warrant exercise price), for gross
proceeds of $14,375,000, before deducting underwriting discounts
and offering expenses.
The Company intends to use the net proceeds of
the offering to fund working capital and for general corporate
purposes.
ThinkEquity acted as sole book-running manager
for the offering.
A registration statement on Form S-1 (File No.
333-280887) relating to the securities being offered was filed with
the Securities and Exchange Commission (“SEC”) and became effective
on August 6, 2024. This offering is being made only by means of a
prospectus. Copies of the final prospectus may be obtained from
ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.
The final prospectus has been filed with the SEC and is available
on the SEC’s website located at http://www.sec.gov.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Scorpius Holdings,
Inc.Scorpius Holdings Inc. is an integrated large molecule
contract development and manufacturing organization (CDMO) focused
on rapidly advancing biologic and cell therapy programs to the
clinic and beyond. Scorpius offers a broad array of analytical
testing, process development, and manufacturing services to
pharmaceutical and biotech companies at its state-of-the-art
facilities in San Antonio, TX. With an experienced team and new,
purpose-built U.S. facilities, Scorpius is dedicated to transparent
collaboration and flexible, high-quality biologics
biomanufacturing. For more information, please visit
www.scorpiusbiologics.com.
Forward-Looking StatementsThis
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. In some cases
forward-looking statements can be identified by terminology such as
"may," "should," "potential," "continue," "expects," "anticipates,"
"intends," "plans," "believes," "estimates," and similar
expressions and include statements regarding the intended use of
proceeds. Important factors that could cause actual results to
differ materially from current expectations include, among others,
the ability to complete the proposed offering, and other factors
described in the Company’s annual report on Form 10-K for the year
ended December 31, 2023, subsequent quarterly report on Form 10-Q
and any other filings the Company makes with the SEC. The
information in this presentation is provided only as of the date
presented, and the Company undertakes no obligation to update any
forward-looking statements contained in this press release on
account of new information, future events, or otherwise, except as
required by law.
For Investor Relations
Inquiries:
David Waldman+1
(919)-289-4017investorrelations@nighthawkbio.com
Scorpius (AMEX:SCPX)
Historical Stock Chart
From Jul 2024 to Aug 2024
Scorpius (AMEX:SCPX)
Historical Stock Chart
From Aug 2023 to Aug 2024